aTyr Pharma, Inc.(US:ATYR) Globenewswireยท2025-10-15 19:30Core Points - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage [5] Group 1 - The class action lawsuit allows investors who purchased aTyr Pharma common stock during the specified period to seek compensation without any out-of-pocket fees through a contingency fee arrangement [2] - Investors interested in serving as lead plaintiff must file a motion with the Court by December 8, 2025 [1][3] - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4] Group 2 - The complaint alleges that aTyr Pharma provided overwhelmingly positive statements while concealing material adverse facts about the drug's efficacy, leading to investor damages when the truth was revealed [5] - No class has been certified yet, meaning investors are not represented by counsel unless they retain one [7]